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Population-based screening using Papanicolaou (Pap) smears and 
treatment programmes of pre-malignant lesions of the cervix has 
significantly reduced the morbidity and mortality associated with 
cervical cancer. In developed countries, associated deaths have been 
reduced by 45 - 80%.1-3 
Screening practices differ between countries according to local 
experience and cost. In the UK, systematic screening was introduced in 
1988, and reduced death by cervical cancer by 50%. This programme’s 
screening interval has been 3 - 5 years, but its success has been attributed 
to its coverage, reaching about 80.6% of eligible women by 2004.2 
South Africa (SA) is a middle-income country with many competing 
health needs and a poorly developed infrastructure for colposcopy 
services. The country established a cervical cancer prevention 
programme in 2001, under which women are offered 3 Pap smears 
in a lifetime starting at age 30 years. However, if the first Pap smear 
is performed after the age of 55 years and is normal, only one Pap 
smear will be performed, while women in whom the cytology is 
reported as inadequate are re-screened. Furthermore, women with 
any gynaecological complaint should receive a smear as part of their 
gynaecological examination irrespective of their screening history.4
Cytology has a false-negative rate of 15 - 30%.5,6 In a South African 
study, 10% of cervical cancer cases occurred in women who had been 
screened, but at least 5 years previously. More than 50% occurred in 
women who had never been screened.7 Prospective studies have not 
evaluated screening intervals >5 years between Pap smears. 
Between 2004 and 2006 in Soweto, Johannesburg, a trial 
investigated the use of the diaphragm in preventing HIV infection, 
and also offered a Pap smear at the enrolment visit and again at 
the end of the trial.8 These data allowed us to assess the incidence 
of abnormal cytology after a normal or inadequate Pap smear in a 
setting with a high prevalence of cervical abnormalities.7 We aimed 
to determine the proportion of women who developed an abnormal 
Pap smear within 24 months of a normal Pap smear, in a cohort of 
women in Soweto. Risk factors associated with an incident abnormal 
Pap smear were explored. 
Methods
Between November 2003 and December 2005, the Soweto site of 
the Methods for Improving Reproductive Health in Africa (MIRA) 
trial recruited 1 028 women from the surrounding community and 
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Background. A screening programme for cervical cancer has been implemented in South Africa (SA) with intervals of 10 years after a 
normal cytological result. There are no studies that evaluate repeat screening at a shorter interval in SA. 
Objectives. (i) To find the incidence of cytological abnormalities on a repeat test after a report of normal cytology or an inadequate Pap 
smear; and (ii) to explore the factors associated with an abnormal cytology on repeat testing. 
Methods. This was a secondary data analysis of a randomised controlled trial of diaphragm, lubricant gel and condoms v. condoms in the 
prevention of HIV infection. HIV-negative women were recruited between November 2003 and December 2005, with a normal Pap smear 
at entry. Observation time was from the first Pap smear to the date of the repeat Pap smear. Explanatory variables used were baseline, 
excepting any new HIV infection. 
Results. The incidence of cytological abnormalities was 6.48% yearly in women with a previously normal Pap smear and 11.71% yearly in 
women with an inadequate smear result (p=0.03). The incidence of high-grade squamous intra-epithelial lesions (HSILs) was <0.5%. Factors 
associated with abnormal cytology were a history of ectopic pregnancy (odds ratio (OR) 9.25; confidence interval (CI) 1.78 - 48.02; p=0.01), 
number of male partners (OR 1.12; CI 1.03 - 1.22; p=0.01), history of vaginal discharge (OR 13.95; CI 1.18 - 164.47; p=0.04), and incident 
HIV infection (OR 6.56; CI 1.14 - 38.16; p=0.04). 
Conclusion. The incidence of HSILs is low in the first 2 years after a normal or inadequate Pap smear, even in a setting with a high 
prevalence of cytological abnormalities.
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district clinics (ClinicalTrials.gov number NCT00211459). This 
study is a secondary analysis of data from this randomised open-
label trial, which compared the effectiveness of using condoms 
alone to using a combination of condoms, the latex diaphragm 
(Ortho-McNeil Pharmaceutical, Raritan, NJ, USA) and a lubricant 
gel (Replens, Lil’ Drug Store Products, Cedar Rapids, IA, USA) 
for preventing HIV infection in women. Participants received an 
HIV prevention package that included HIV/sexually transmitted 
infection (STI) pre- and post-test counselling, treatment of 
treatable laboratory-diagnosed STIs, condom promotion and risk-
reduction counselling. 
Participants were HIV-uninfected, sexually active women, aged 
18 - 49 years. Eligible subjects had a cervix, consented to be treated 
for any treatable STI and did not desire a pregnancy at the time. 
Participants were monitored quarterly for a period of 12 - 24 months 
for HIV infection and other STIs.
Interviews conducted at enrolment were used to obtain 
demographic information and medical and gynaecological 
history. Women also underwent a pelvic examination at the first 
visit and all were offered a Pap smear (protocol required that 
all women who had not had a Pap smear in the preceding 12 
months be offered a Pap smear). Women were also offered a Pap 
smear at exit. 
The Pap smears were conventional smears performed by nurse 
clinicians, and reported on by the SA National Health Laboratory 
Service (NHLS) cytopathology department. This accredited 
laboratory has stringent internal and external quality control. The 
recommendations for management of Pap smear abnormalities 
stipulated that any Pap smear without an endo- or ectocervical 
component was inadequate and had to be repeated, even when the 
descriptive diagnosis was ‘within normal limits’. Any Pap report of 
low-grade squamous intra-epithelial lesions or atypical squamous 
cells of undetermined significance (ASCUS) was repeated in 6 
months. Meanwhile, reports of high-grade squamous intra-epithelial 
lesions (HSILs) or atypical glandular cells were referred to the 
Colposcopy Clinic at Chris Hani Baragwanath Academic Hospital 
for further management. 
Only STI tests at enrolment (prevalence data) and incident 
HIV test results were used. Polymerase chain reaction (PCR) 
testing was performed for Chlamydia trachomatis, Neisseria 
gonorrhoeae and Trichomonas vaginalis. A blood test was 
provided at enrolment and at exit for herpes simplex virus 2 
(Focus HSV2 enzyme-linked immunosorbent assay (ELISA)) 
and syphilis (rapid plasma reagin (RPR) and Treponema pallidum 
haemagglutinin (TPHA)). A finger-prick blood sample or venous 
puncture was obtained for rapid HIV-1/2 testing (Oraquick and 
Determine tests). 
Women with equivocal results underwent confirmatory laboratory 
ELISA testing. Participants were notified about the HIV result 
and post-test counselling was provided to both HIV-positive and 
-negative women. 
We conducted a secondary analysis of the MIRA trial data. 
Pap smear results were coded as normal/inadequate or abnormal 
(ASCUS, LSIL, HSIL or more severe). We defined observation time as 
the date from the first Pap smear (enrolment) to the date of the repeat 
Pap smear. All explanatory variables used were baseline variables, 
except new HIV infection. 
The data analysis was performed using STATA statistical software 
(version 10). Using standard statistical methods, we compared the 
distributions of explanatory variables among women who continued to 
have a normal Pap smear v. those who developed abnormal cytology. 
We performed a bivariate analysis using a logistic regression to 
determine factors associated with the outcome. We entered all variables 
found to be significant in bivariate testing (p<0.2) and used a backward 
selection procedure to arrive at a final multivariate model. 
To compare the risk of an abnormal Pap smear in those who 
had a normal Pap smear at baseline with those who had an 
inadequate Pap smear at baseline, we used standard methods 
for time-to-event data to determine time to abnormal cervical 
cytology. 
The Human Research Ethics Committee (Medical) of the University 
of the Witwatersrand approved the study protocol for the MIRA trial 
(M031111) and granted ethical clearance for the use of the data in 
this secondary analysis (M090676). 
Results
Among those eligible for the study, 850 women underwent a repeat 
Pap smear; 97 (11.41%) had an abnormal Pap smear at entry and 
were excluded (Fig. 1). These abnormalities were comprised of 
ASCUS (31 cases; 3.65%), LSIL (51 cases; 6%) and HSIL (15 cases; 
1.76%).
The incidence of cytological abnormalities in this group of women 
(baseline Pap normal or inadequate) was 7.33% per annum. The incidence 
of cytological abnormalities was 6.48 % in women with a previously 
normal Pap and 11.71% in women with an inadequate smear result. Fig. 2 
depicts the risk of having an abnormal Pap smear. The median follow-up 
time was 297 days (interquartile range (IQR) 182 - 455).
The log-rank test for equality of survivor function indicates that 
there is a statistically significant difference in the risk of a cytological 
abnormality after a normal Pap smear when compared with an 
inadequate one (p=0.03).
Of both the normal and inadequate Pap smears <0.5% had an 
HSIL reported on their subsequent Pap smear and the rest of the 
abnormalities were LSIL and ASCUS (Table 1). 
Fig. 1. Flow of participants eligible for the study. ASCUS = atypical 
squamous cells of undetermined significance; LSIL = low-grade squamous 
intraepithelial neoplasialesion; HSIL = high-grade squamous intraepithelial 
lesions.
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The subjects’ median age was 28 years (IQR 22 - 35) and the 
median number of years they had been educated was 12 (IQR 10 - 
12). Participants were not asked about smoking or alcohol use. 
Types of contraception being used at the time of enrolment 
were: combined oral contraception (n=58; 7.70%); injectable 
hormonal contraception; (n=223; 29.61%); progestogen-only pills 
(n=20; 2.66%); intra-uterine contraceptive device (n=7; 0.93%); and 
withdrawal or natural methods (17; 2.26%).
The association between condom usage and the incidence of an 
abnormal Pap smear was contradictory: while there where fewer 
women with cervical abnormalities in those randomised to the 
control group (condoms only), there was no association in women 
who said they used condoms at the last intercourse or were currently 
using them (Table 2). 
The median parity in this group was 2 (IQR 1 - 3), with a 
range of 0 - 7. The difference in pregnancy history (live births, 
vaginal deliveries, miscarriages and abortions) in women who had a 
subsequent normal or abnormal Pap smear was not significant. An 
ectopic pregnancy in the past was associated with an abnormal Pap 
smear, but this association was not statistically significant (4 (4.82%) 
v. 10 (1.61%); p=0.7). 
The mean age of first intercourse was 17.58 years (standard 
deviation (SD) ±2.12; range 11 - 27). There was no statistical 
difference in having a subsequent abnormal Pap smear in women 
who had had an earlier sexual debut (p = 0.24) or in women who had 
had sex in exchange for money (p = 0.11). Women with an increased 
number of sexual partners were more likely to have an abnormal 
Pap smear on repeat testing (mean 4.85 (SD ±3.40) v. mean 3.48 
(SD ±2.73); p=0.00). The trial excluded women who performed <3 
coital acts in the month; therefore, it was not meaningful to assess 
difference by coital frequency. Age at first intercourse was not 
reflected in any statistical difference in the outcome (Table 3).
Table 4 shows the association between the risk of developing an 
abnormal cytology on Pap smear, and whether subjects had a history 







Normal 460 (85.98) 177 (81.19) 637 (84.59)
LSIL 39 (7.29) 13 (5.96) 52 (6.91)
ASCUS 18 (3.36) 11 (5.05) 29 (3.85)
HSIL 2 (0.37) 1 (0.46) 3 (0.40)
Inadequate 16 (2.99) 16 (7.34) 32 (4.2)
Total, N 535 218 753
LSIL = low-grade squamous intra-epithelial lesion; ASCUS = atypical squamous cells of undetermined significance; HSIL = high-grade squamous intra-epithelial lesion. 
Fig. 2. The risk of having an abnormal Pap smear.
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 suggestive of an STI in the preceding 3 months or alternatively 
confirmatory tests of STIs. A history of a vaginal discharge in 
the preceding 3 months, or symptoms of an STI, were important 
differences between those who did and those who did not develop 
cytological abnormalities. Clinical findings for STIs were discovered 
on examination, rather than following complaints from the women, 
as could be expected in a research setting. 
There were no statistical differences in incident cervical cytological 
abnormalities among women with objective evidence of an STI at 
baseline and no infection (Table 4). Incident STIs such as chlamydia 
(n=32; 4.25%), gonorrhoea (n=13; 1.73%) and trichomonas 
(n=38; 5.05%) were not associated with an increase in cytological 
abnormalities. 
Incident HIV infection was associated with a 6-fold increase 
in the risk of an abnormal Pap smear. An abnormal discharge in 
the last 3 months and having had an ectopic pregnancy at any 
time also increased the risk. Having used a condom after the 
last intercourse had no effect, but being allocated to the control 
(condom) arm of the study reduced the risk by approximately 
58% (Table 5). 
Discussion
The SA cervical screening guidelines predict a reduction of 
cervical cancer of between 64 - 70% with a screening interval of 10 
years.4,9 An evaluation of screening intervals shows that screening 
is associated with a reduced incidence of cervical cancer, ranging 
from 84% with 5-year intervals to 94% when the screening was 
performed every 2 years, in both cases in women aged 35 - 64 
years.10 
We used the presence of any cytological abnormality as an outcome 
measure, because this would mean that the particular woman is at 
risk of cervical cancer, albeit with a different degree of risk. Of note 
was a low incidence of HSILs, which is the threshold for treatment 
in our setting: 0.46% and 0.37% in the inadequate and adequate Pap 
smear groups, respectively. The prevalence of HSILs in women who 
were recruited for the study was 1.76%. 







Age at first intercourse
Mean 17.58 (SD ±2.12)
Range 11 - 27
Mean 17.32 (SD ±1.78) Mean 17.61 (SD ±2.15) 0.24* 
0.18‡ 
Sex in exchange for money
n=17 (2.26%)
4 (4.76%) 13 (1.94%) 0.11§
Number of male partners
Mean 4.02 (SD ±2.90)
Range 1 - 26
Mean 4.85 (SD ±3.40) Mean 3.84 (SD ±2.73) 0.00*
Average sex in the preceding 3 months:
Mean 9.46 (SD ±5.12)
Range 3 - 40
Mean 9.46 (SD ±4.96)
Median 8 (IQR 4 - 12)
Mean 9.46 (SD ±4.96)







t-test (unequal variances); 
§
Fisher’s exact.







Randomised to the intervention arm 
(diaphragm)
n=388 (51.53%)
53 (63.10) 335 (50.07) 0.02 (χ2)
Randomised to the control arm
n=365 (48.47%)
31 (36.90) 334 (49.93)
Condoms used at last vaginal sex
n=438 (71.57%)
46 (64.79) 392 (72.46) 0.18 (χ2)
Ever used condoms
n=586 (77.82%)
64 (76.19) 522 (78.03) 0.70 (χ2)
Current condom use (at baseline)
n=506 (67.20%)
53 (63.10) 453 (67.71) 0.40 (χ2)
Female condoms used at last intercourse
n=27 (4.41%)
4 (5.63) 23 (4.25) 0.54*
*Fisher’s exact used when there were <5 observations in a cell.
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The Australian National Health and Medical Research Council 
Guidelines recommend that all pathologists report normal Pap 
smear results with a recommendation that the next Pap smear is due 
in 2 years, irrespective of the presence or absence of endocervical 
component or of reactive change.11 
There was no testing for human papillomavirus (HPV) in our 
study; if we use abnormal cytology as a proxy for HPV infection 
then its incidence is much higher than that of herpes or HIV. In 
women with a normal Pap smear at recruitment, the incidence 
of herpes was 3.32%, HIV 1.33% and HPV (using abnormal Pap 
smears as a marker) at least 7.33%. An HIV infection incidence of 
1.33% is much lower than in the MIRA study, where it was 4%8 (as 
explained in Fig. 1, we excluded all women with an abnormal Pap 
smear at baseline).
HPV infection was not shown to be a risk factor for HIV infection 
in a Zimbabwean study,12 but because women with dysplasia on their 
entry Pap were excluded from this study it may be that dysplastic 
cervical epithelium accounted for the higher rate of HIV infection in 
the parent study.8 
Condom use reduces HPV transmission,13 persistence14 and 
seropositivity.15 A history of male condom usage was protective 
against acquiring an abnormal Pap smear in this study, but this was 
not statistically significant. Assignment to the condoms-only arm 
of the MIRA trial, however, was associated with a 50% lower risk 
of an abnormal Pap smear than assignment to the diaphragm arm 
(p=0.01). 
Asking subjects about ‘condom use at last intercourse’ is considered 
a good way to assess use because it reduces recall bias. However, in 
this analysis this criterion did not differ between the two groups, 
even on stratifying by randomisation. The prevalence of female 
condom use was low in this group of women and was discouraged 
by the researchers owing to probable problems with fitting of the 
diaphragm for women in the intervention arm (diaphragm, lubricant 
and condoms).
A limitation of the study was that only women who agreed to be 
treated for an STI that had been detected by a laboratory test were 
eligible for inclusion. The the rate of cytological abnormality may also 
differ in women symptomatic for STI presenting at a gynaecological 
clinic. The study sample was too small for stratifying into different 
age categories, and to fully evaluate risk factors. Pap smears have 
a poor sensitivity and therefore we were not able to evaluate 
sensitivity. Although Pap smear screening has a high specificity, only 
colposcopically directed biopsies can confirm the exact grade of 
the lesion. The study numbers were also too small for us to use the 
presence of HSILs as an outcome measure.
The study’s strengths included that its population comprised 
sexually active women from Soweto who had a high prevalence of 
cervical cancer, and loss to follow-up was approximately 7%.







Have you ever been treated for an STI?
153 (20.51%)
n=746
22 (26.51%) 131 (19.76%) 0.15 (χ2)
Number of times treated 
Mean 1.26 (SD ±0.89)
Mean 1.91 (SD ±1.95) Mean 1.15 (SD ±0.49) 0.00* 
Symptoms suggestive of an STI
n=68 (9.12%)
15 (18.07) 53 (7.99) 0.00 (χ2)
Abnormal bleeding in the last 3 months
n=22 (2.95%)
1 (1.20) 21 (3.17) 0.28†
Vaginal discharge on history in the last 3 
months
n=37 (4.96%)
11 (13.25) 26 (3.92) 0.00 (χ2)
Chlamydia at entry
n=41 (3.44%)
5 (5.95) 36 (5.38) 0.84†
Gonorrhea at entry
n=7 (0.93%)
1 (1.19) 6 (0.90) 0.57†
Trichomonas
n=12 (1.59%)
1 (1.19) 11 (1.64) 1†
WR positive 
n=10 (4.55%) 
1 (5) 9(4.5) 1†
HSV at entry
n=482 (64.01%)
56 (66.67) 426 (63.68) 0.81 (χ2)
Incident HIV
n=10 (1.33%)
2 (2.38) 8 (1.20) 0.20†
*t-test †Fisher’s exact
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The results of this study suggest that it would be safe for the 
next Pap to be delayed for at least 1 year even in women with an 
inadequate Pap smear result. 
The lower incidence of HIV warrants further study on whether 
cervical dysplasia, and not just HPV infection, is an independent risk 
factor for HIV infection.
Disclosure. This paper was part of a dissertation submitted for an MSc 
degree (Epidemiology & Biostatistics) by Y Adam to the University of the 
Witwatersrand. 
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Table 5. Univariate and multivariate analysis
Univariate analysis Multivariate analysis
OR 95% CI p-value OR  95% CI p-value
Age 0.98 0.95 - 1.01 0.17  0.97 0.89 - 1.05 0.42
Contraception-barrier
Used a male condom at the last vaginal sexual 
intercourse
0.70 0.41 - 1.18 0.18 0.75 0.40 - 1.39 0.36
Condoms as opposed to diaphragm 0.59 0.37 - 0.94 0.03 0.51 0.27 - 0.97 0.04
Pregnancy history
Had an ectopic pregnancy 3.31 1.01 - 10.79 0.05 9.25 1.78 - 48.02 0.01
Sexual history
Coitarche at age ≤19 years v. >19 years 0.52 0.23 - 1.17 0.11 0.83 0.32 - 2.14 0.70
Number of male partners 1.10 1.03 - 1.18 0.00 1.12 1.03 - 1.22 0.01
STI
Treated for a STI 1.46 0.87 - 2.47 0.15 0.98 0.50 - 1.90 0.95
Number of times treated 2.43 1.21 - 4.89 0.01 6.59 1.54 - 28.19 0.01
History of vaginal discharge 3.74 1.78 - 7.89 0.00 13.95 1.18 - 164.5 0.04
HIV 2.08 0.43 - 10.00 0.36 6.58 1.14 - 38.16 0.04
